Lowest Price Guaranteed From USD 4,799
Published
July 2023
Slides
222
View Count
6118
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global allogeneic cell therapy market is estimated to be worth USD 0.54 Million in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 14.5% during the forecast period 2023-2035. Allogeneic cell therapies refer to off-the-shelf therapies that are isolated from donor tissues (such as cord blood and bone marrow), processed ex vivo in the labs and then administered into patients / cryopreserved in a cell bank. Since these therapies are manufactured in advance, they are readily available and eliminate the need for individualized production for every patient. Owing to their various benefits, such as improved and consistent product quality (due to rigorous quality control measures taken during processing), reduced cost (due to centralized manufacturing process) and flexibility in approaching the same donor or choosing a different donor (in case the patient requires another course of the treatment), allogeneic cell therapies have gained significant traction in the healthcare industry. Further, recent advancements in gene editing technologies, such as CRISPR/Cas9, have opened up new possibilities for allogeneic cell therapies by enabling precise genetic modifications in the donor cells in order to enhance their therapeutic properties and reduce the risk of immune rejection.
Over the past few years, a number of allogeneic cell therapies targeting a myriad of disorders, including hematological malignancies (such as multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological disorders, musculoskeletal disorders and autoimmune / inflammatory disorders, have received approval from various regulatory authorities, globally. In December 2022, the European Commission approved the first allogeneic T-cell therapy, namely Ebvallo, (developed by Atara Biotherapeutics) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. In addition, the FDA approved an allogenic mesenchymal stem cell therapy, Osteocel® Plus (developed by NuVasive), for the treatment of degenerative disc disease. Driven by the continuous efforts of both industry and non-industry players, rising prevalence of chronic diseases and non-malignant disorders, and challenges associated with production of autologous cell therapies, the global allogeneic cell therapies market is likely to witness substantial market growth during the forecast period.
The Allogeneic Cell Therapy Market, 2023-2035 - Distribution by Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell and Regulatory T-Cell), Source of Cell (Peripheral Blood, Bone Marrow, Umbilical Cord Blood, Adipose Tissue and Placenta), Target Indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), Therapeutic Area (Oncological Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune / Inflammatory Disorders and Post-Transplant Infections), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size and future opportunities for the allogenic cell therapy developers, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the allogeneic therapy market report are briefly discussed below.
Allogeneic cell therapy and autologous cell therapy are two distinct approaches in regenerative medicine market. In autologous cell therapy, the cells are derived from the patient's own body, processed ex-vivo and reintroduced into the same patient; this personalized approach ensures compatibility and minimizes the risk of immune rejection. However, these therapies require a longer production time, as each patient's cells need to be individually processed. On the other hand, allogeneic cell therapy involves the use of cells from a healthy donor; these collected donor cells might be given directly to a genetically similar patient or added to a cell bank. Allogeneic cell therapy has various advantages, including immediate accessibility, scalability and cost-effectiveness, however, it may involve the risk of immune rejection.
Allogenic cell therapy market landscape features the presence of close to 195 large, mid-sized and small companies developing allogeneic cell therapies, for a wide range of indications. It is worth highlighting that over 470 allogenic cell therapies are currently being evaluated in different preclinical / clinical stages, either as monotherapies or in combination with other drugs. In April 2023, Gamida Cell received approval from the FDA for its umbilical cord blood-derived, allogeneic stem cell therapy, Omisirge® (omidubicel-onlv); the therapy is used to treat patients with hematologic malignancies. The growing demand for novel allogeneic cell therapies, approvals from various regulatory bodies and continuous advancements in cell therapy manufacturing process, are expected to drive the allogeneic cell therapies market growth during the forecast period.
Over the years, companies involved in the development of allogeneic cell therapies have made significant efforts to conduct clinical trials for evaluating the efficacy of allogeneic cell therapies, for the treatment of various disorders, including infectious diseases (adenovirus infection, coronavirus infection and cytomegalovirus infection), neurological disorders (autism, bipolar depression, Parkinson’s disease, stroke) and oncological disorders (acute myeloid leukemia, biliary tract cancer, breast cancer and multiple myeloma). Over 365 clinical trials have been registered across different geographical regions to evaluate various allogenic cell therapies. Of these trials, majority (~180) were registered in North America and maximum number of patients (9,300) were observed to be enrolled in clinical trials conducted in North America, accounting for about 55% of the overall enrollment. It is worth mentioning that Fundamenta Therapeutics is conducting the maximum number of trials in this industry for different types of cancers, such as acute lymphoblastic leukemia, acute lymphoblastic lymphoma and non-Hodgkin’s lymphoma. In addition, an allogeneic CAR T cell therapy, ALLO-715 (developed by Allogene) for the treatment of relapsed / refractory multiple myeloma has demonstrated positive results in the Phase I clinical trials.
Several stakeholders have been forging alliances with other industry / non-industry players for the development of allogeneic cell therapies. It is worth highlighting that, since 2019, over 90 strategic partnerships have been established in the allogeneic cell therapy market. Majority of such deals are focused on research and development, product / technology licensing, and development and commercialization of allogenic cell therapies. In March 2023, Tessa Therapeutics entered into a research and development agreement with US National Cancer Institute for Tessa’s allogeneic CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, TT11X, useful in the treatment of non-Hodgkin’s lymphoma. In January 2022, Allogene Therapeutics signed a licensing agreement with Antion Biosciences for the latter company’s miRNA technology (miCAR™) in order to advance multiplex gene silencing tool (useful in the development of innovative allogeneic CAR T cell therapy).
The growing interest in allogeneic cell therapy market can be validated by the fact that in the past four years, close to USD 8.8 billion has been invested by several investors based across the globe, in companies engaged in the development of allogeneic cell therapies. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, Legend Biotech raised the maximum funding amount (USD 487.3 million) through initial public offering. In December 2022, Gamida Cell announced the closing of a convertible term loan of USD 25 million with Highbridge Capital Management; the funding is planned to be used to advance the company’s allogeneic NK cell therapy pipeline.
The global allogeneic cell therapy market is estimated to be worth USD 0.54 Million in 2023. Driven by the increasing need for novel allogenic cell therapies, along with growing development pipeline and encouraging clinical trial results, the allogenic cell therapies market is anticipated to grow at a CAGR of 14% during the forecast period. Specifically, in terms of target disease indication, the market is anticipated to be driven by allogeneic cell therapies being developed for the treatment of lymphoma and leukemia.
Majority of the companies developing allogeneic cell therapies are headquartered in North America, followed by companies based in Asia Pacific. Consequently, more than 60% of the global market of allogeneic cell therapies is anticipated to be captured by players based in North America, in 2035. The factors responsible for the growth of the allogeneic cell therapy market in North America include the rising incidence of acute as well as chronic disorders, increasing FDA approvals for novel allogenic cell therapies and growing adoption of innovative therapies in the developed countries. In addition, the US government has been actively involved in providing reimbursement for expensive allogeneic cell therapies, recognizing their potential to revolutionize healthcare and improve patient outcomes.
Examples of the key allogeneic cell therapy companies (based on number of products under development; the complete list of players is available in the full report) include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellenkos, Cell2Cure, Celularity, Cellular Biomedicine Group, CHABiotech, CRISPR Therapeutics, Fate Therapeutics, Fundamenta Therapeutics, GC Cell, Hope Biosciences, Immunity Bio, Mesoblast, Nanjing Bioheng Biotech, Orca Bio, Pluristem Therapeutics, Poseida Therapeutics and Stemedica Cell Technologies. This market report also includes an easily searchable excel database of all the allogeneic therapy companies (developers) worldwide.
Several recent developments have taken place in the field of allogenic cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in the allogenic cell therapy market, across different segments, as defined in the below table:
| Key Report Attributes | Details | |
|
Base Year |
2023 |
|
|
Forecast Period |
2023 – 2035 |
|
|
Market Size 2023 |
$4 million |
|
|
CAGR |
14% |
|
|
Type of Cell Therapy |
|
|
|
Source of Cell |
|
|
|
Target Indication |
|
|
|
Therapeutic Area |
|
|
|
Key Geographical Regions |
|
|
|
Customization Scope |
|
|
|
Excel Data Packs (Complimentary) |
|
|
The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the market report includes:
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the allogeneic cell therapies market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of cell therapy (virus-specific T-cell, stem cell and regulatory T-cell), source of cell (peripheral blood, bone marrow, umbilical cord blood, adipose tissue and placenta), target indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), therapeutic area (oncological disorders, neurological disorders, musculoskeletal disorders, autoimmune / inflammatory disorders, post-transplant infections), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with some of the key industry stakeholders.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Type of Cell Therapy
4.1.4. Analysis by Source of Cell
4.1.5. Analysis by Dosing Frequency
4.1.6. Analysis by Type of Therapy
4.1.7. Analysis by Target Patient Segment
4.1.8. Analysis by Target Indication
4.1.9. Analysis by Therapeutic Area
4.2. Allogeneic Cell Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Most Active Players: Analysis by Number of Therapies
5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.3. Allogeneic Cell Therapies: Partnerships and Collaborations
5.3.1 Analysis by Year of Partnership
5.3.2. Analysis by Type of Partnership
5.3.3. Analysis by Year and Type of Partnership
5.3.4. Analysis by Type of Cell Therapy
5.3.5. Analysis by Therapeutic Area
5.3.6. Analysis by Type of Partner
5.3.7. Most Active Players: Analysis by Number of Partnerships
5.3.8. Analysis by Geography
5.3.8.1. Intercontinental and Intracontinental Deals
5.3.8.2. Local and International Deals
6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
6.3.1. Analysis by Year of Investment
6.3.2. Analysis by Amount Invested
6.3.3. Analysis by Type of Funding
6.3.4. Analysis of Amount Invested by Type of Funding
6.3.5. Analysis of Amount Invested by Year and Type of Funding
6.3.6. Analysis by Type of Investor
6.3.7. Analysis by Type of Therapy
6.3.8. Analysis by Geography
6.3.9. Leading Investors: Analysis by Number of Instances
6.3.10. Most Active Players: Analysis by Number of Instances
6.3.11. Most Active Players: Analysis by Amount Invested
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Status
7.2.3. Analysis by Trial Registration Year and Trial Status
7.2.4. Analysis by Trial Registration Year and Patients Enrolled
7.2.5. Analysis by Trial Status and Patients Enrolled
7.2.6. Analysis by Trial Phase
7.2.7. Analysis by Study Design
7.2.8. Analysis by Trial Status, Trial Phase and Geography
7.2.9. Analysis by Type of Sponsor
7.2.10. Most Active Industry Players: Analysis by Number of Trials
7.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
7.2.12. Analysis by Geography
8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
8.2.1. Analysis by Type of KOL
8.2.2. Analysis by Qualification
8.2.3. Analysis by Type of Organization
8.2.4. Analysis by Affiliated Organization
8.2.5. Analysis by Target Disease Indication
8.2.6. Analysis by Geographical Location of KOLs
8.2.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
8.2.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
8.2.9 Most Prominent KOLs: Peer Group 3 (Study Chair)
8.2.10. Most Prominent KOLs: Analysis by RA Score
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.3.1. Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035
9.3.1.1. Allogeneic Cell Therapy Market for Stem Cell Therapies, 2023-2035
9.3.1.2. Allogeneic Cell Therapy Market for Virus-specific T-cell Therapies, 2023-2035
9.3.1.3. Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, 2029-2035
9.3.2. Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035
9.3.2.1. Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, 2023-2035
9.3.2.2. Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035
9.3.2.3. Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2025-2035
9.3.2.4. Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, 2023-2035
9.3.2.5. Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035
9.3.2.6. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.3. Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035
9.3.3.1. Allogeneic Cell Therapy Market for Infectious Disease, 2023-2035
9.3.3.2. Allogeneic Cell Therapy Market for Chronic Heart Failure, 2023-2035
9.3.3.3. Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035
9.3.3.4. Allogeneic Cell Therapy Market for Ischemic Stroke, 2024-2035
9.3.3.5. Allogeneic Cell Therapy Market for Hematological Cancer, 2023-2035
9.3.3.6. Allogeneic Cell Therapy Market for Bone Diseases 2023-2035
9.3.3.7. Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035
9.3.3.8. Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035
9.3.3.9. Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, 2026-2035
9.3.3.10. Allogeneic Cell Therapy Market for Epidermolysis Bullosa, 2027-2035
9.3.3.11. Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035
9.3.3.12. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.4. Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035
9.3.4.1. Allogeneic Cell Therapy Market for Post-Transplant Infections, 2023-2035
9.3.4.2. Allogeneic Cell Therapy Market for Cardiovascular Disorders, 2023-2035
9.3.4.3. Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, 2023-2035
9.3.4.4. Allogeneic Cell Therapy Market for Cerebrovascular Disorders, 2024-2035
9.3.4.5. Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035
9.3.4.6. Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035
9.3.4.7. Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035
9.3.4.8. Allogeneic Cell Therapy Market for Genetic Disorders, 2026-2035
9.3.4.8. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.5. Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035
9.3.5.1. Allogeneic Cell Therapy Market in North America, 2023-2035
9.3.5.1.1. Allogeneic Cell Therapy Market in the US, 2023-2035
9.3.5.1.2. Allogeneic Cell Therapy Market in Canada, 2024-2035
9.3.5.2. Allogeneic Cell Therapy Market in Europe, 2023-2035
9.3.5.2.1. Allogeneic Cell Therapy Market in the UK, 2023-2035
9.3.5.2.2. Allogeneic Cell Therapy Market in Germany, 2023-2035
9.3.5.2.3. Allogeneic Cell Therapy Market in France, 2023-2035
9.3.5.2.4. Allogeneic Cell Therapy Market in Italy, 2023-2035
9.3.5.2.5. Allogeneic Cell Therapy Market in Spain, 2023-2035
9.3.5.2.6. Allogeneic Cell Therapy Market in Rest of Europe, 2023-2035
9.3.5.3. Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035
9.3.5.3.1. Allogeneic Cell Therapy Market in India, 2023-2035
9.3.5.3.2. Allogeneic Cell Therapy Market in Australia, 2026-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Taiwan, 2027-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Japan, 2023-2035
9.3.5.3.4. Allogeneic Cell Therapy Market in Korea, 2023-2035
9.3.5.3.5. Allogeneic Cell Therapy Market in Malaysia, 2023-2035
9.3.5.3.6. Allogeneic Cell Therapy Market in Israel, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035
9.4.1. Revascor / MPC-150-IM / Rexlemestrocel-L
9.4.1.1. Sales Forecast (USD Million)
9.4.1.2. Net Present Value
9.4.1.3. Value Creation Analysis
9.4.2. Alofisel / Darvadstrocel / Cx601
9.4.2.1. Sales Forecast (USD Million)
9.4.2.2. Net Present Value
9.4.2.3. Value Creation Analysis
9.4.3. MultiStem® (Athersys)
9.4.3.1. Sales Forecast (USD Million)
9.4.3.2. Net Present Value
9.4.3.3. Value Creation Analysis
9.4.4. Tab-cel® / tabelecleucel / ATA129
9.4.4.1. Sales Forecast (USD Million)
9.4.4.2. Net Present Value
9.4.4.3. Value Creation Analysis
9.4.5. MDR-101
9.4.5.1. Sales Forecast (USD Million)
9.4.5.2. Net Present Value
9.4.5.3. Value Creation Analysis
9.4.6. PLX-PAD
9.4.6.1. Sales Forecast (USD Million)
9.4.6.2. Net Present Value
9.4.6.3. Value Creation Analysis
9.4.7. OMISIRGE / Omidubicel-onlv
9.4.7.1. Sales Forecast (USD Million)
9.4.7.2. Net Present Value
9.4.7.3. Value Creation Analysis
9.4.8. Orca-T
9.4.8.1. Sales Forecast (USD Million)
9.4.8.2. Net Present Value
9.4.8.3. Value Creation Analysis
9.4.9. Ryoncil
9.4.9.1. Sales Forecast (USD Million)
9.4.9.2. Net Present Value
9.4.9.3. Value Creation Analysis
9.4.10. Stempeucel®
9.4.10.1. Sales Forecast (USD Million)
9.4.10.2. Net Present Value
9.4.10.3. Value Creation Analysis
9.4.11. Viralym-M / ALVR105 / Posoleucel
9.4.11.1. Sales Forecast (USD Million)
9.4.11.2. Net Present Value
9.4.11.3. Value Creation Analysis
9.4.12. Trinity Evolution®
9.4.12.1. Sales Forecast (USD Million)
9.4.12.2. Net Present Value
9.4.12.3. Value Creation Analysis
9.4.13. CAP-1002
9.4.13.1. Sales Forecast (USD Million)
9.4.13.2. Net Present Value
9.4.13.3. Value Creation Analysis
9.4.14. Osteocel® Plus
9.4.14.1. Sales Forecast (USD Million)
9.4.14.2. Net Present Value
9.4.14.3. Value Creation Analysis
9.4.15. MPC-06-ID / Rexlemestrocel-L
9.4.15.1. Sales Forecast (USD Million)
9.4.15.2. Net Present Value
9.4.15.3. Value Creation Analysis
9.4.16. AB-205 / E-CEL cells
9.4.16.1. Sales Forecast (USD Million)
9.4.16.2. Net Present Value
9.4.16.3. Value Creation Analysis
9.4.17. allo-APZ2-OTS
9.4.17.1. Sales Forecast (USD Million)
9.4.17.2. Net Present Value
9.4.17.3. Value Creation Analysis
9.4.18. Trinity ELITE
9.4.18.1. Sales Forecast (USD million)
9.4.18.2. Net Present Value
9.4.18.3. Value Creation Analysis
9.4.19. CYP-004
9.4.19.1. Sales Forecast (USD Million)
9.4.19.2. Net Present Value
9.4.19.3. Value Creation Analysis
9.4.20. Cytovir CMV T-cells
9.4.20.1. Sales Forecast (USD Million)
9.4.20.2. Net Present Value
9.4.20.3. Value Creation Analysis
9.4.21. CARTISTEM®
9.4.21.1. Sales Forecast (USD Million)
9.4.21.2. Net Present Value
9.4.21.3. Value Creation Analysis
9.4.22. Grafix®
9.4.22.1. Sales Forecast (USD Million)
9.4.22.2. Net Present Value
9.4.22.3. Value Creation Analysis
9.4.23. ELIXCYTE
9.4.23.1. Sales Forecast (USD Million)
9.4.23.2. Net Present Value
9.4.23.3. Value Creation Analysis
9.4.24. TEMCELL® HS
9.4.24.1. Sales Forecast (USD Million)
9.4.24.2. Net Present Value
9.4.24.3. Value Creation Analysis
9.4.25. ALLO-ASC-DFU
9.4.25.1. Sales Forecast (USD Million)
9.4.25.2. Net Present Value
9.4.25.3. Value Creation Analysis
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Glycostem Therapeutics
10.2.1 Company Snapshot
10.2.2. Interview Transcript: Troels Jordansen (Chief Executive Officer)
10.3. Mesoblast
10.3.1 Company Snapshot
10.3.2. Interview Transcript: Eric Rose (Chief Medical Officer)
10.4. Triumvira Immunologics
10.4.1. Company Snapshot
10.4.2. Interview Transcript: Andreas Bader (Chief Scientific Officer)
10.5. Celyad Oncology
10.5.1. Company Snapshot
10.5.2. Interview Transcript: Vincent Brichard (Vice President)
11. APPENDIX I: TABULATED DATA
12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Key Opinion Leaders
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Manufacturing Process of Allogeneic Cell Therapy
Figure 3.2 Advantages Offered by Allogeneic Cell Therapy
Figure 3.3 Challenges Associated with Allogeneic Cell Therapy
Figure 4.1 Allogeneic Cell Therapies: Distribution by Phase of Development
Figure 4.2 Allogeneic Cell Therapies: Distribution by Route of Administration
Figure 4.3 Allogeneic Cell Therapies: Distribution by Type of Cell Therapy
Figure 4.4 Allogeneic Cell Therapies: Distribution by Source of Cell
Figure 4.5 Allogeneic Cell Therapies: Distribution by Dosing Frequency
Figure 4.6 Allogeneic Cell Therapies: Distribution by Type of Therapy
Figure 4.7 Allogeneic Cell Therapies: Distribution by Target Patient Segment
Figure 4.8 Allogeneic Cell Therapies: Distribution by Target Indication
Figure 4.9 Allogeneic Cell Therapies: Distribution by Therapeutic Area
Figure 4.10 Allogeneic Cell Therapies Developers: Distribution by Year of Establishment
Figure 4.11 Allogeneic Cell Therapies Developers: Distribution by Company Size
Figure 4.12 Allogeneic Cell Therapies Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Therapies
Figure 5.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2019-2023
Figure 5.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 5.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 5.4 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 5.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 5.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 5.7 Most Active Players: Distribution by Number of Partnerships
Figure 5.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 5.9 Partnerships and Collaborations: Local and International Deals
Figure 6.1 Funding and Investments: Distribution by Year of Investment, 2019-2023
Figure 6.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 6.3 Funding and Investments: Distribution by Type of Funding
Figure 6.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 6.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 6.6 Funding and Investments: Distribution by Type of Investor
Figure 6.7 Funding and Investments: Distribution by Type of Therapy
Figure 6.8 Funding and Investments: Distribution by Geography (Region-wise)
Figure 6.9 Funding and Investments: Distribution by Geography (Country-wise)
Figure 6.10 Leading Investors: Distribution by Number of Instances
Figure 6.11 Most Active Players: Distribution by Number of Instances
Figure 6.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Industry Players: Analysis by Number of Trials
Figure 7.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 7.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Figure 7.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Figure 8.1 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Figure 8.2 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Figure 8.3 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 8.4 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 8.5 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 8.6 Allogeneic Cell Therapies KOL Analysis: Geographical Distribution of KOLs (Region-wise)
Figure 8.7 Allogeneic Cell Therapies KOL Analysis: Geographical Distribution of KOLs (Country-wise)
Figure 8.8 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 8.9 Most Prominent KOLs: Peer Group 2 (Study Directors)
Figure 8.10 Most Prominent KOLs: Peer Group 3 (Study Chair)
Figure 8.11 Most Prominent KOLs: Distribution by RA score
Figure 9.1 Global Allogeneic Cell Therapy Market, 2023-2035 (USD Million)
Figure 9.2 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035 (USD Million)
Figure 9.3 Allogeneic Cell Therapy Market for Stem Cell Therapies, 2023-2035 (USD Million)
Figure 9.4 Allogeneic Cell Therapy Market for Virus-Specific T-cell Therapies, 2023-2035 (USD Million)
Figure 9.5 Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, 2029-2035 (USD Million)
Figure 9.6 Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035 (USD Million)
Figure 9.7 Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, 2023-2035 (USD Million)
Figure 9.8 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035 (USD Million)
Figure 9.9 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2025-2035 (USD Million)
Figure 9.10 Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, 2023-2035 (USD Million)
Figure 9.11 Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035 (USD Million)
Figure 9.12 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Million)
Figure 9.13 Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035 (USD Million)
Figure 9.14 Allogeneic Cell Therapy Market for Infectious Disease, 2023-2035 (USD Million)
Figure 9.15 Allogeneic Cell Therapy Market for Chronic Heart Failure, 2023-2035 (USD Million)
Figure 9.16 Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035 (USD Million)
Figure 9.17 Allogeneic Cell Therapy Market for Ischemic Stroke, 2024-2035 (USD Million)
Figure 9.18 Allogeneic Cell Therapy Market for Hematological Cancer, 2023-2035 (USD Million)
Figure 9.19 Allogeneic Cell Therapy Market for Bone Disease, 2023-2035 (USD Million)
Figure 9.20 Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035 (USD Million)
Figure 9.21 Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035 (USD Million)
Figure 9.22 Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, 2026-2035 (USD Million)
Figure 9.23 Allogeneic Cell Therapy Market for Epidermolysis Bullosa, 2027-2035 (USD Million)
Figure 9.24 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035 (USD Million)
Figure 9.25 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Million)
Figure 9.26 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 9.27 Allogeneic Cell Therapy Market for Post-Transplant Infections, 2023-2035 (USD Million)
Figure 9.28 Allogeneic Cell Therapy Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 9.29 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders 2023-2035 (USD Million)
Figure 9.30 Allogeneic Cell Therapy Market for Cerebrovascular Disorders, 2024-2035 (USD Million)
Figure 9.31 Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 9.32 Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035 (USD Million)
Figure 9.33 Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 9.34 Allogeneic Cell Therapy Market for Genetic Disorders, 2026-2035 (USD Million)
Figure 9.35 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Million)
Figure 9.36 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 9.37 Allogeneic Cell Therapy Market in North America, 2023-2035 (USD Million)
Figure 9.38 Allogeneic Cell Therapy Market in the US, 2023-2035 (USD Million)
Figure 9.39 Allogeneic Cell Therapy Market in Canada, 2024-2035 (USD Million)
Figure 9.40 Allogeneic Cell Therapy Market in Europe, 2023-2035 (USD Million)
Figure 9.41 Allogeneic Cell Therapy Market in the UK, 2023-2035 (USD Million)
Figure 9.42 Allogeneic Cell Therapy Market in Germany, 2023-2035 (USD Million)
Figure 9.43 Allogeneic Cell Therapy Market in France, 2023-2035 (USD Million)
Figure 9.44 Allogeneic Cell Therapy Market in Spain, 2023-2035 (USD Million)
Figure 9.45 Allogeneic Cell Therapy Market in Italy, 2023-2035 (USD Million)
Figure 9.46 Allogeneic Cell Therapy Market in Rest of Europe, 2023-2035 (USD Million)
Figure 9.47 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 9.48 Allogeneic Cell Therapy Market in India, 2023-2035 (USD Million)
Figure 9.49 Allogeneic Cell Therapy Market in Australia, 2026-2035 (USD Million)
Figure 9.50 Allogeneic Cell Therapy Market in Taiwan, 2027-2035 (USD Million)
Figure 9.51 Allogeneic Cell Therapy Market in Japan, 2023-2035 (USD Million)
Figure 9.52 Allogeneic Cell Therapy Market in Korea, 2023-2035 (USD Million)
Figure 9.53 Allogeneic Cell Therapy Market in Malaysia, 2023-2035 (USD Million)
Figure 9.54 Allogeneic Cell Therapy Market in Israel, 2023-2035 (USD Million)
Figure 9.55 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.56 Alofisel / Darvadstrocel / Cx601 (Takeda): Sales Forecast, till 2035 (USD Million)
Figure 9.57 MultiStem® (Athersys): Sales Forecast, till 2035 (USD Million)
Figure 9.58 Tab-cel® / tabelecleucel / ATA129 (Atara Biotherapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.59 MDR-101 (Medeor Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.60 PLX-PAD (Pluristem Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.61 OMISIRGE / Omidubicel-onlv (Gamida Cell): Sales Forecast, till 2035 (USD Million)
Figure 9.62 Orca-T (Orca Bio): Sales Forecast, till 2035 (USD Million)
Figure 9.63 Ryoncil (Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.64 Stempeucel® (Stempeutics Research): Sales Forecast, till 2035 (USD Million)
Figure 9.65 Viralym-M / ALVR105 / Posoleucel (Allovir): Sales Forecast, till 2035 (USD Million)
Figure 9.66 Trinity Evolution® (Orthofix): Sales Forecast, till 2035 (USD Million)
Figure 9.67 CAP-1002 (Capricor Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.68 Osteocel® Plus (NuVasive): Sales Forecast, till 2035 (USD Million)
Figure 9.69 MPC-06-ID / Rexlemestrocel-L (Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.70 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, till 2035 (USD Million)
Figure 9.71 allo-APZ2-OTS (RHEACELL): Sales Forecast, till 2035 (USD Million)
Figure 9.72 Trinity ELITE (Orthofix): Sales Forecast, till 2035 (USD Million)
Figure 9.73 CYP-004 (Cynata Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.74 Cytovir CMV T-cells (Kuur Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.75 CARTISTEM® (Medipost): Sales Forecast, till 2035 (USD Million)
Figure 9.76 Grafix® (Osiris Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.77 ELIXCYTE (UnicoCell Biomed): Sales Forecast, till 2035 (USD Million)
Figure 9.78 TEMCELL® HS (JCR Pharmaceutical / Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.79 ALLO-ASC-DFU (Anterogen): Sales Forecast, till 2035 (USD Million)
Table 4.1 List of Allogeneic Cell Therapies
Table 4.2 List of Allogeneic Cell Therapies Developers
Table 5.1 Allogeneic Cell Therapies: List of Partnerships and Collaborations, 2019-2023
Table 6.1 Allogeneic Cell Therapies: List of Funding and Investments, 2019-2023
Table 7.1. Allogeneic Cell Therapies: List of Clinical Trials, 2019-2023
Table 8.1. Allogeneic Cell Therapies: List of Key Opinion Leaders (KOLs)
Table 9.1 Allogeneic Cell Therapies: List of Forecasted Therapies
Table 11.1 Market Landscape: Distribution by Phase of Development
Table 11.2 Market Landscape: Distribution by Route of Administration
Table 11.3 Market Landscape: Distribution by Type of Cell Therapy
Table 11.4 Market Landscape: Distribution by Source of Cell
Table 11.5 Market Landscape: Distribution by Dosing Frequency
Table 11.6 Market Landscape: Distribution by Type of Therapy
Table 11.7 Market Landscape: Distribution by Target Patient Segment
Table 11.8 Market Landscape: Distribution by Target Indication
Table 11.9 Market Landscape: Distribution by Therapeutic Area
Table 11.10 Market Landscape: Distribution by Year of Establishment
Table 11.11 Market Landscape: Distribution by Company Size
Table 11.12 Market Landscape: Distribution by Location of Headquarters
Table 11.13 Market Landscape: Distribution by Number of Therapies
Table 11.14 Partnerships and Collaborations: Distribution by Year of Partnership, 2019-2023
Table 11.15 Partnerships and Collaborations: Distribution by Type of Partnership
Table 11.16 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 11.17 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 11.18 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 11.19 Partnerships and Collaborations: Distribution by Type of Partner
Table 11.20 Most Active Players: Distribution by Number of Partnerships
Table 11.21 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 11.22 Partnerships and Collaborations: Local and International Deals
Table 11.23 Funding and Investments: Distribution by Year of Investment, 2019-2023
Table 11.24 Funding and Investments: Distribution by Amount Invested (USD Million)
Table 11.25 Funding and Investments: Distribution by Type of Funding
Table 11.26 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 11.27 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 11.28 Funding and Investments: Distribution by Type of Investor
Table 11.29 Funding and Investments: Distribution by Type of Therapy
Table 11.30 Funding and Investments: Distribution by Geography (Region-wise)
Table 11.31 Funding and Investments: Distribution by Geography (Country-wise)
Table 11.32 Leading Investors: Distribution by Number of Instances
Table 11.33 Most Active Players: Distribution by Number of Instances
Table 11.34 Most Active Players: Distribution by Amount Invested (USD Million)
Table 11.35 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Table 11.36 Clinical Trial Analysis: Distribution by Trial Status
Table 11.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 11.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 11.39 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 11.40 Clinical Trial Analysis: Distribution by Trial Phase
Table 11.41 Clinical Trial Analysis: Distribution by Study Design
Table 11.42 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 11.43 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 11.44 Most Active Industry Players: Analysis by Number of Trials
Table 11.45 Most Active Non-Industry Players: Analysis by Number of Trials
Table 11.46 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Table 11.47 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Table 11.48 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Table 11.49 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Table 11.50 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 11.51 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 11.52 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Table 11.53 Allogeneic Cell Therapies KOL Analysis: Distribution by Geographical Location of KOLs
Table 11.54 Most Prominent KOLs: Distribution by RA score
Table 11.55 Global Allogeneic Cell Therapy Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.56 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035 (USD Million)
Table 11.57 Allogeneic Cell Therapy Market for Stem Cell Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.58 Allogeneic Cell Therapies Market for Virus-specific T-cell Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.59 Allogeneic Cell Therapy Market for Regulatory T-cell Therapies: Conservative, Base and Optimistic Scenarios, 2029-2035 (USD Million)
Table 11.60 Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035 (USD Million)
Table 11.61 Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.62 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.63 Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.64 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies: Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Million)
Table 11.65 Allogeneic Cell Therapy Market for Placenta-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.66 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.67 Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035 (USD Million)
Table 11.68 Allogeneic Cell Therapy Market for Infectious Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.69 Allogeneic Cell Therapy Market for Chronic Heart Failure: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.70 Allogeneic Cell Therapy Market for Crohn’s Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.71 Allogeneic Cell Therapy Market for Ischemic Stroke: Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Million)
Table 11.72 Allogeneic Cell Therapy Market for Hematological Cancer: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.73 Allogeneic Cell Therapy Market for Bone Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.74 Allogeneic Cell Therapy Market for Critical Limb Ischemia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.75 Allogeneic Cell Therapy Market for Graft versus Host Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.76 Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy: Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Million)
Table 11.77 Allogeneic Cell Therapy Market for Epidermolysis Bullosa: Conservative, Base 8and Optimistic Scenarios, 2027-2035 (USD Million)
Table 11.78 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.79 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.80 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Table 11.81 Allogeneic Cell Therapy Market for Post Transplant Infections: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.82 Allogeneic Cell Therapy Market for Cardiovascular Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.83 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.84 Allogeneic Cell Therapy Market for Cerebrovascular Disorders: Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Million)
Table 11.85 Allogeneic Cell Therapy Market for Oncological Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.86 Allogeneic Cell Therapy Market for Musculoskeletal Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.87 Allogeneic Cell Therapy Market for Neurological Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.88 Allogeneic Cell Therapy Market for Genetic Disorders: Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Million)
Table 11.89 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.90 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 11.91 Allogeneic Cell Therapy Market in North America: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.92 Allogeneic Cell Therapy Market in the US: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.93 Allogeneic Cell Therapy Market in Canada: Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Million)
Table 11.94 Allogeneic Cell Therapy Market in Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.95 Allogeneic Cell Therapy Market in the UK: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.96 Allogeneic Cell Therapy Market in Germany: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.97 Allogeneic Cell Therapy Market in France: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.98 Allogeneic Cell Therapy Market in Italy: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.99 Allogeneic Cell Therapy Market in Spain: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.100 Allogeneic Cell Therapy Market in Rest of Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.101 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.102 Allogeneic Cell Therapy Market in India: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.103 Allogeneic Cell Therapy Market in Australia: Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Million)
Table 11.104 Allogeneic Cell Therapy Market in Taiwan: Conservative, Base and Optimistic Scenarios, 2027-2035 (USD Million)
Table 11.105 Allogeneic Cell Therapy Market in Japan: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.106 Allogeneic Cell Therapy Market in Korea: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.107 Allogeneic Cell Therapy Market in Malaysia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.108 Allogeneic Cell Therapy Market in Israel: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.109 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.110 Alofisel / Darvadstrocel / Cx601 (Takeda): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.111 MultiStem® (Athersys): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.112 Tab-cel® / tabelecleucel / ATA129 (Atara Biotherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.113 MDR-101 (Medeor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.114 PLX-PAD (Pluristem Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.115 OMISIRGE / Omidubicel-onlv (Gamida Cell): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.116 Orca-T (Orca Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.117 Ryoncil (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.118 Stempeucel® (Stempeutics Research): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.119 Viralym-M / ALVR105 / Posoleucel (Allovir): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.120 Trinity Evolution® (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.121 CAP-1002 (Capricor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.122 Osteocel® Plus (NuVasive): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.123 MPC-06-ID / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.124 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.125 allo-APZ2-OTS (RHEACELL): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.126 Trinity ELITE (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.127 CYP-004 (Cynata Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.128 Cytovir CMV T-cells (Kuur Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.129 CARTISTEM® (Medipost): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.130 Grafix® (Osiris Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.131 ELIXCYTE (UnicoCell Biomed): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.132 TEMCELL® HS (JCR Pharmaceutical, Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.133 ALLO-ASC-DFU (Anterogen): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://www.sciencedirect.com/topics/engineering/allogeneic
Source 2: https://www.mskcc.org/cancer-care/clinical-trials/19-392
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES